Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Bouscary

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
British Journal of Haematology|May 16, 2023
Tandem versus single haematopoietic stem cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSAA Marouf, N Molinari, D Sibon, et al.
Leukemia Research|January 15, 2008
Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomideC Kelaidi, S Park, S Brechignac, et al.
Leukemia Research|July 22, 2008
Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromesJ Tamburini, C Elie, S Park, et al.
Leukemia|June 23, 2006
Nucleophosmin status may influence the therapeutic decision in de novo acute myeloid leukemia with normal karyotypeV Bardet, L D Costa, C Elie, et al.
Leukemia|May 29, 2010
Tandem versus single autologous peripheral blood stem cell transplantation as post-remission therapy in adult acute myeloid leukemia patients under 60 in first complete remission: results of the multicenter prospective phase III GOELAMS LAM-2001 trialP Chevallier, L Fornecker, B Lioure, et al.
Leukemia|December 7, 2011
The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemiaL Willems, N Chapuis, A Puissant, et al.
Leukemia|January 17, 2013
A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapseS Park, N Chapuis, F Saint Marcoux, et al.
Leukemia|October 30, 2013
Long-term results of a randomized phase 3 trial comparing idarubicin and daunorubicin in younger patients with acute myeloid leukaemiaC Récher, M C Béné, B Lioure, et al.
Leukemia|September 16, 2017
RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemiaM-A Hospital, A Jacquel, F Mazed, et al.
Leukemia|March 11, 2017
High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cellsL Poulain, P Sujobert, F Zylbersztejn, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
British Journal of Haematology|May 16, 2023
Tandem versus single haematopoietic stem cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSAA Marouf, N Molinari, D Sibon, et al.
Leukemia Research|January 15, 2008
Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomideC Kelaidi, S Park, S Brechignac, et al.
Leukemia Research|July 22, 2008
Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromesJ Tamburini, C Elie, S Park, et al.
Leukemia|June 23, 2006
Nucleophosmin status may influence the therapeutic decision in de novo acute myeloid leukemia with normal karyotypeV Bardet, L D Costa, C Elie, et al.
Leukemia|May 29, 2010
Tandem versus single autologous peripheral blood stem cell transplantation as post-remission therapy in adult acute myeloid leukemia patients under 60 in first complete remission: results of the multicenter prospective phase III GOELAMS LAM-2001 trialP Chevallier, L Fornecker, B Lioure, et al.
Leukemia|December 7, 2011
The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemiaL Willems, N Chapuis, A Puissant, et al.
Leukemia|January 17, 2013
A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapseS Park, N Chapuis, F Saint Marcoux, et al.
Leukemia|October 30, 2013
Long-term results of a randomized phase 3 trial comparing idarubicin and daunorubicin in younger patients with acute myeloid leukaemiaC Récher, M C Béné, B Lioure, et al.
Leukemia|September 16, 2017
RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemiaM-A Hospital, A Jacquel, F Mazed, et al.
Leukemia|March 11, 2017
High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cellsL Poulain, P Sujobert, F Zylbersztejn, et al.
Pageof 8